Market Tracker

07/22 5:16pm ET

Exelixis Inc (NASDAQ:EXEL)

8.68
Delayed Data
As of Jul 22
 +0.09 / +1.05%
Today’s Change
3.55
Today|||52-Week Range
8.74
+53.90%
Year-to-Date
Cancer Stocks: 2 to Buy, 1 to Avoid
Jul 23 / MotleyFool.com - Paid Partner Content
Pfizer Reports Positive Data on Kidney Cancer Drug Sutent
Jul 11 / Zacks.com - Paid Partner Content
5 Stocks to Buy and Hold for the Next Decade
Jul 20 / MotleyFool.com - Paid Partner Content
Here's How Pfizer's Protecting Its Kidney Cancer Drug From New Competitors
Jul 10 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close8.59
Today’s open8.67
Day’s range8.62 - 8.74
Volume2,952,977
Average volume (3 months)5,408,442
Market cap$2.0B
Dividend yield--
Data as of 3:59pm ET, 07/22/2016

Growth & Valuation

Earnings growth (last year)+41.30%
Earnings growth (this year)-20.37%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+48.03%
P/E ratioNM
Price/Sales31.75
Price/Book--

Competitors

 Today’s
change
Today’s
% change
NKTRNektar Therapeutics-0.19-1.23%
DBVTDBV Technologies SA+0.47+1.37%
INCRINC Research Holding...-0.16-0.37%
LXRXLexicon Pharmaceutic...+0.34+2.21%
Data as of 3:59pm ET, 07/22/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)-$0.28
Annual revenue (last year)$37.2M
Annual profit (last year)-$169.7M
Net profit margin-456.63%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Michael M. Morrissey
Chief Financial Officer &
Executive Vice President
Christopher J. Senner
Corporate headquarters
South San Francisco, California

Forecasts